Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder

Phase 2 Withdrawn Dennis Charney National Institutes of Health (NIH) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test a candidate drug, Org 24448,in a phase II clinical trial in adult patients with moderately treatment-resistant unipolar major depressive disorder.

Timeline

Start: 2005-03
Primary completion: 2005-03
Completion: 2005-03

Outcome

Outcome not reported

Stopped: “protocol cancelled”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FARAMPATOR	Small molecule	750 mg	—

Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder

Summary

Timeline

Outcome

Drugs

Indications